10:58 AM EDT, 06/25/2025 (MT Newswires) -- Jaguar Health ( JAGX ) said Wednesday it plans to seek European regulatory approval for Canalevia for the treatment of general diarrhea in dogs.

The company said it intends to submit a dossier to the European Medicines Agency's Committee for Veterinary Medical Products that contains the updated analysis of the company's completed study of Canalevia.

If found acceptable by the regulator, the company said it will then submit a marketing authorization application, which, if approved, will make Canalevia marketable for the treatment of general diarrhea in dogs in all European Union member states.

The company said Canalevia, under the Canalevia-CA1 name, has conditional approval from the US Food and Drug Administration for the treatment of chemotherapy-induced diarrhea in dogs.

Jaguar Health ( JAGX ) shares were down 3.3% in recent trading.

Price: 2.95, Change: -0.10, Percent Change: -3.28